Thus, this PPARγ agonist proved to effectively inhibit the growth of an NB tumour xenograft, in keeping with similar findings obtained using PPARγ agonists against other types of tumour xenografts, such as colorectal (Katoh et al, 2004; Yoshizumi et al, 2004; Cesario et al, 2006; Shimazaki et al, 2008), lung (Nemenoff, 2007; Hazra et al, 2008; Roman, 2008), prostate (Annicotte et al, 2006), bladder and ovarian cancer (Kassouf et al, 2006; Xin et al, 2007). This evidence concerns the gene PPARG and ovarian cancer.